Slide 1: Results Presentation Half Year Ended 30 June 2017
RESULTS PRESENTATION HALF YEAR ENDED 30 JUNE 2017 21 August 2017
Slide 2: Vita Life Sciences Overview
VITA LIFE SCIENCES OVERVIEW • Asia Pacific & Australian based pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements • 4 major consumer brands • Over 800 registered SKUs of vitamins and supplements sold in 7
Slide 3: Group Summary
GROUP SUMMARY • Group sales of $17.7 million for the 6 months to June 2017, marginally lower that the previous corresponding period (PCP) • Net profit after tax of $1.5 million for the 6 months to June 2017, 17.5% down on the PCP • Interim 2017 dividend of 1.5 cents declared. This dividend is fully
Slide 4: Half Year 2017 Results
HALF YEAR 2017 RESULTS Established markets: Australia, Singapore and Malaysia had mixed results • Australia: Domestic market sales remained steady; however exports sales of Herbs of Gold products sold in China were affected by slower uptake in the 1st 6 months of 2017. • Malaysia: Revenue and EBIT f
Slide 5: Half Year 2017 Results
HALF YEAR 2017 RESULTS Other Asia: performance was mixed • Vietnam continued to grow steadily and performance was in line with expectations. Continued investment will be a key focus for this market. • Thailand recovering, although sales marginally lower than the previous corresponding period • Indon
Slide 6: Segment Results Australia
SEGMENT RESULTS Revenue ($m) AUSTRALIA 10 Sales revenue: $7.6m (HY16 $8.1m) 5 • Herbs of Gold ‒ Revenue base for products sold within Australian was sustained in a competitive Australian market - ‒ Sales via international distribution agreement were 2016 2017 slow, as anticipated • VitaScience in th
Slide 7: Segment Results Malaysia
SEGMENT RESULTS Revenue ($m) MALAYSIA 10 Sales revenue: $5.8m flat on HY16: $5.9m 5 • Malaysian business performed exceptionally well • Revenue improved by 9% in local currency over HY16. Depreciating Malaysia Ringgit and a strong Australia Dollar resulted in a flat revenue result. - 2016 2017 EBIT:
Slide 8: Segment Results Singapore
SEGMENT RESULTS Revenue ($m) SINGAPORE 5 4 Sales revenue of $3.1m, flat on HY16 $3.1m 3 • Highly competitive market and difficult trading terms 2 EBIT of $0.6m (HY16 $0.8m) 1 • Margins impacted by higher advertising and - promotional expenditures including higher incentives to 2016 2017 retailers to
Slide 9: Interim Dividend & Cashflow
INTERIM DIVIDEND & CASHFLOW • Interim dividend declared of 1.5 cents per share for HY17 (1.5 cents HY16) • Interim dividend will be fully franked. Directors anticipate future dividends to be fully franked. • Dividend reinvestment plan is currently suspended • The increase in gross operating cashflow
Slide 10: Senior Management
SENIOR MANAGEMENT Appointed Mr Chin Khoo as group CFO on the 1st of May. Appointment of Mrs Melissa Pereira as Head of Marketing on the 1st of July. Appointment of a new Asian Regional CEO, Dr Edward Choo, to head our business in Asia. He will join us on the 14th September 2017 and brings with him s
Slide 11: Shareholder Update
SHAREHOLDER UPDATE Trading update Based on trading to June 2017 and no material changes within the Company’s regions of operation, the Directors provide the following guidance for the 2017 full year; Full year revenue guidance of ∼$38m; Full year EBIT guidance of $5.0m to $5.5m. 11
Slide 12: Appendix
APPENDIX 12
Slide 13: Appendix – Profit & Loss
APPENDIX 1 – PROFIT & LOSS Half year ended June 2017 2016 $m $m Revenue 17.7 18.1 EBITDA 2.6 3.1 EBIT 2.4 3.0 Profit before tax 2.4 3.0 Profit after tax 1.5 1.9 EPS (Diluted – cents) 2.75 3.28 Dividend (cents / share) 1.50 1.50 13
Slide 14: Appendix – Balance Sheet
APPENDIX 2 – BALANCE SHEET Balance Sheet as at June 2017 December 2016 $m $m Current assets 21.1 21.7 Non-current assets 10.2 10.6 Total assets 31.3 32.4 Current liabilities 6.2 6.8 Non-current liabilities 2.1 2.3 Total Liabilities 8.4 9.2 Net Assets 22.9 23.2 14
Slide 15: Appendix – Cash Flow
APPENDIX 3 – CASH FLOW Cash Flow for the half year ended 2017 2016 $m $m Receipts from customers 19.8 19.6 Payments to suppliers and employees (18.1) (18.6) Gross operating cash flow 1.8 1.0 EBITDA 2.5 3.0 Gross operating cash flow / EBITDA 72.1% 32.8% Net interest (paid) / received (0.1) - Income t
Slide 16: Contact
CONTACT Telephone: +61 2 9545 2633 Website: vitalifesciences.com Email: enquiries@vitalifesciences.com Head Office: 1/102 Bath Road, Kirrawee, NSW 2232 16
Slide 17: Disclaimer
DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to a